#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hyperphagia Craniocerebral injury B-cell small lymphocytic lymphoma recurrent Fusarium infection Hodgkin's disease Mitochondrial DNA depletion Extra-osseous Ewing's sarcoma metastatic Carcinoid syndrome Hepatobiliary cancer Peritoneal mesothelioma malignant ROHHAD syndrome B-cell small lymphocytic lymphoma Epilepsy with myoclonic-atonic seizures Hepatic angiosarcoma Chondrodystrophy More trials…

    Learn about Rare Diseases

    Mast cell activation syndrome – Basic Information Epidermolysis bullosa – Trials in Disease Nodal marginal zone B-cell lymphoma – Life with Disease Ehlers-Danlos syndrome Hereditary optic atrophy – Diagnostics Skin angiosarcoma – Trials in Disease Mucopolysaccharidosis I – Life with Disease Primary hyperoxaluria Indolent systemic mastocytosis – Basic Information Stevens-Johnson syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Albiglutide ALXN1920 Imlifidase Capivasertib Venlafaxine Hydrochloride Fentanyl Axicabtagene Ciloleucel Chloride Ion Gad20-209-Fsp-A4 Chlorpromazine Hydrochloride IMELASOMERAN Doxorubicin Hydrochloride Sqy51 Ly3437943 Sodium Dalbavancin Radium Ra 223 Dichloride Sodium S-Lactate Solution Lbl-007 Metyrapone Sulodexide More therapies…

    Learn about Your Condition

    Nephrotic syndrome Multifocal motor neuropathy Marginal zone lymphoma Tendon rupture Impaired gastric emptying Bronchiectasis Pancreatic carcinoma stage IV Deafness traumatic Retinopathy of prematurity Frostbite Chronic granulomatous disease Pericarditis Apathy Peritoneal sarcoma Supranuclear palsy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Gaucher’s disease type I

  • Phase 3 Safety and Efficacy Trial of FLT201 Gene Therapy in Patients with Gaucher Disease Type 1 Using Drug Combination

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Gaucher’s disease type I
    Investigated Drugs:
    • Adeno-Associated Viral Vector Serotype S3 Containing Codon-Optimised Expression Cassette Encoding Human Beta-Glucocerebrosidase Variant
    • Methylprednisolone Hydrogen Succinate
    • Prednisolone
    Spain

  • Study on the Safety of LY3884961 for Patients with Type 1 Gaucher Disease

    Not yet recruiting

    1 1 1 1
    Investigated Drugs:
    • Adeno-Associated Viral Vector Serotype 9 Expressing Codon-Optimized Human Gba Gene
    • Eculizumab
    • Methylprednisolone
    Germany Spain

  • Study of Eliglustat alone or with Imiglucerase in children and adolescents aged 2-17 years with Gaucher disease type 1 and type 3

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Gaucher’s disease type I
    • Gaucher’s disease type III
    Investigated Drugs:
    • Eliglustat Tartrate
    • Imiglucerase
    France Italy Spain

  • Study on the Long-term Safety of FLT201 for Patients with Gaucher Disease Type 1

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Gaucher’s disease type I
    Investigated Drugs:
    • Adeno-Associated Viral Vector Serotype S3 Containing Codon-Optimised Expression Cassette Encoding Human Beta-Glucocerebrosidase Variant
    Spain

  • Study of Venglustat and Imiglucerase for Adult Patients with Gaucher Disease Type 3

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Gaucher’s disease type I
    • Gaucher’s disease type III
    Investigated Drugs:
    • Imiglucerase
    • Venglustat
    Germany

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!